Drug intelligence / Profile preview

Ruanshang Pian

Development stage: Unknown
Lead developer: Liaoning University of Traditional Chinese Medicine
Administration: Oral

Overview

Ruanshang Pian is a Traditional Chinese Medicine (TCM) formulation developed by the Liaoning University of Traditional Chinese Medicine and the Institute of Chinese Materia Medica. It is specifically designed for the treatment of acute closed soft tissue injuries, particularly those presenting with the TCM syndrome of Qi stagnation and blood stasis. The medication is formulated as an oral tablet. Clinical development has reached Phase II, where studies have focused on evaluating its efficacy in symptom relief and safety profile, as well as determining the optimal therapeutic dosage for soft tissue trauma.

Brand names: Ruanshang Pian
Other names: Ruanshang tablets

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on Ruanshang Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ruanshang Pian.

Explore the full profile